ArticleApplied biochemistry and biotechnology2026
Repurposing Lapatinib and Tucatinib as Dual Inhibitors of Bcl-2 and TYMS in Breast Cancer: Insights from Transcriptomic, Computational and Cellular Assays.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer remains a leading cause of cancer related deaths worldwide. HER2-positive subtypes, marked by HER2 receptor over expression often exhibit aggressive behavior. Advances in high-throughput sequencing have revealed new molecular targets, paving the way for more precise therapies. Targeted therapies inhibit HER2 signaling, improving clinical outcomes. However, tumour resistance and survival pathways remain challenges. Identifying alternative targets of HER2 inhibitors may uncover new pathways to suppress tumour growth and improve treatment efficacy. Publicly available RNA-Seq datasets were processed in Galaxy to profile differential gene expression. Bcl-2, an anti-apoptotic regulator and TYMS, a key enzyme in DNA synthesis have emerged as lead candidates. Twenty literatures derived HER2 inhibitors were docked against both proteins, and 100 ns molecular dynamics simulations refined binding stability and validated by functional in-vitro cellular assays. Lapatinib showed the strongest binding to Bcl-2, while tucatinib had the lowest binding energy for TYMS. Both drugs displayed binding profiles resembling their respective controls. Lapatinib and tucatinib are both targeted therapies primarily used to treat HER2-positive cancers. Our study suggests that these agents may also exert effects beyond their primary targets, including potential roles in modulation of Bcl-2 for lapatinib and TYMS inhibition for tucatinib. Furthermore, we observed correlation between Bcl-2 and TYMS expression in breast cancer suggesting that their interplay may influence tumour progression, prognosis, and therapy responsiveness. Our study highlights that lapatinib and tucatinib, beyond HER2 inhibition, may also target Bcl-2 and TYMS respectively. This dual functionality could improve therapeutic strategies against HER2-positive breast cancer. Further biochemical and clinical validation will be necessary to confirm their mechanistic significance.
Indexed as
Identifiers
41793646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.